← All trials
NCT05177510
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- Mar 31, 2024
- First posted
- Jan 4, 2022
- Last posted
- Apr 1, 2022
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- University of LondonStudy chair
- University of LondonStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.